• STRIDE Trial: Effects of Semaglutide in Patients With Peripheral Artery Disease

  • Apr 29 2025
  • Duración: 10 m
  • Podcast

STRIDE Trial: Effects of Semaglutide in Patients With Peripheral Artery Disease

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Patients with peripheral artery disease (PAD) often experience significant walking difficulties, and there are limited therapies available to improve their mobility. Investigation made through the STRIDE (Effects of Semaglutide on Functional Capacity in Patients With Type 2 Diabetes and Peripheral Arterial Disease) trial focused on semaglutide, a drug known for promoting weight loss, reducing inflammation, and lowering the risk of heart attack or stroke, to determine if it could enhance the functional abilities of PAD patients.

    In this interview, Drs. Alison Bailey and Marc Bonaca discuss how the STRIDE trial data supports the use of semaglutide for individuals with PAD and type 2 diabetes, highlighting its cardiometabolic, cardiovascular, and kidney benefits, as well as its ability to improve function, symptoms, and overall quality of life.

    Subscribe on Apple Podcasts | Subscribe to ACCEL

    Más Menos
Más Menos
adbl_web_global_use_to_activate_webcro805_stickypopup

Lo que los oyentes dicen sobre STRIDE Trial: Effects of Semaglutide in Patients With Peripheral Artery Disease

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles